1. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
- Author
-
Lauren Ancel Meyers, Meagan C. Fitzpatrick, Seyed M. Moghadas, Burton H. Singer, Joanne M. Langley, Affan Shoukat, Kathleen M. Neuzil, Chad R. Wells, Alison P. Galvani, Kevin Zhang, and Thomas N. Vilches
- Subjects
0301 basic medicine ,Microbiology (medical) ,education.field_of_study ,United States ,outbreak simulation ,pandemic ,COVID-19 ,vaccines ,business.industry ,Incidence (epidemiology) ,Population ,Attack rate ,Outbreak ,Vaccine efficacy ,3. Good health ,Herd immunity ,Vaccination ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Infectious Diseases ,Pandemic ,Medicine ,030212 general & internal medicine ,business ,education ,Demography - Abstract
Background Global vaccine development efforts have been accelerated in response to the devastating coronavirus disease 2019 (COVID-19) pandemic. We evaluated the impact of a 2-dose COVID-19 vaccination campaign on reducing incidence, hospitalizations, and deaths in the United States. Methods We developed an agent-based model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and parameterized it with US demographics and age-specific COVID-19 outcomes. Healthcare workers and high-risk individuals were prioritized for vaccination, whereas children under 18 years of age were not vaccinated. We considered a vaccine efficacy of 95% against disease following 2 doses administered 21 days apart achieving 40% vaccine coverage of the overall population within 284 days. We varied vaccine efficacy against infection and specified 10% preexisting population immunity for the base-case scenario. The model was calibrated to an effective reproduction number of 1.2, accounting for current nonpharmaceutical interventions in the United States. Results Vaccination reduced the overall attack rate to 4.6% (95% credible interval [CrI]: 4.3%–5.0%) from 9.0% (95% CrI: 8.4%–9.4%) without vaccination, over 300 days. The highest relative reduction (54%–62%) was observed among individuals aged 65 and older. Vaccination markedly reduced adverse outcomes, with non-intensive care unit (ICU) hospitalizations, ICU hospitalizations, and deaths decreasing by 63.5% (95% CrI: 60.3%–66.7%), 65.6% (95% CrI: 62.2%–68.6%), and 69.3% (95% CrI: 65.5%–73.1%), respectively, across the same period. Conclusions Our results indicate that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection. However, continued compliance with nonpharmaceutical interventions is essential to achieve this impact.
- Published
- 2021